BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15920746)

  • 1. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma.
    Druzgal CH; Chen Z; Yeh NT; Thomas GR; Ondrey FG; Duffey DC; Vilela RJ; Ende K; McCullagh L; Rudy SF; Muir C; Herscher LL; Morris JC; Albert PS; Van Waes C
    Head Neck; 2005 Sep; 27(9):771-84. PubMed ID: 15920746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma.
    Allen C; Duffy S; Teknos T; Islam M; Chen Z; Albert PS; Wolf G; Van Waes C
    Clin Cancer Res; 2007 Jun; 13(11):3182-90. PubMed ID: 17545521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
    Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
    Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum biomarkers in head and neck squamous cell cancer.
    Kaskas NM; Moore-Medlin T; McClure GB; Ekshyyan O; Vanchiere JA; Nathan CA
    JAMA Otolaryngol Head Neck Surg; 2014 Jan; 140(1):5-11. PubMed ID: 24232368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
    Chen Z; Malhotra PS; Thomas GR; Ondrey FG; Duffey DC; Smith CW; Enamorado I; Yeh NT; Kroog GS; Rudy S; McCullagh L; Mousa S; Quezado M; Herscher LL; Van Waes C
    Clin Cancer Res; 1999 Jun; 5(6):1369-79. PubMed ID: 10389921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck.
    Gokhale AS; Haddad RI; Cavacini LA; Wirth L; Weeks L; Hallar M; Faucher J; Posner MR
    Oral Oncol; 2005 Jan; 41(1):70-6. PubMed ID: 15598588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma.
    Kim CH; Lee JS; Kang SO; Bae JH; Hong SP; Kahng H
    Oral Oncol; 2007 Nov; 43(10):1021-5. PubMed ID: 17306605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-6 predicts recurrence and survival among head and neck cancer patients.
    Duffy SA; Taylor JM; Terrell JE; Islam M; Li Y; Fowler KE; Wolf GT; Teknos TN
    Cancer; 2008 Aug; 113(4):750-7. PubMed ID: 18536030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
    Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship and expression of hepatocyte growth factor and vascular endothelial growth factor in serum preoperative and postoperative patients with laryngeal squamous cell cancer].
    Wang Y; Zhao H; Chen J; Liu L; Zhang P; Che J; Wang G
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Dec; 24(24):1112-5. PubMed ID: 21395178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck.
    Hoffmann TK; Sonkoly E; Homey B; Scheckenbach K; Gwosdz C; Bas M; Chaker A; Schirlau K; Whiteside TL
    Head Neck; 2007 May; 29(5):472-8. PubMed ID: 17111427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy.
    De Schutter H; Landuyt W; Verbeken E; Goethals L; Hermans R; Nuyts S
    BMC Cancer; 2005 Apr; 5():42. PubMed ID: 15847702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma.
    Worden B; Yang XP; Lee TL; Bagain L; Yeh NT; Cohen JG; Van Waes C; Chen Z
    Cancer Res; 2005 Aug; 65(16):7071-80. PubMed ID: 16103054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma.
    Homer JJ; Greenman J; Drevs J; Marme D; Stafford ND
    Head Neck; 2002 Aug; 24(8):773-8. PubMed ID: 12203803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
    Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
    Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
    Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
    Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
    Caballero M; Grau JJ; Blanch JL; Domingo-Domenech J; Auge JM; Jimenez W; Bernal-Sprekelsen M
    Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
    Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.
    Tartour E; Deneux L; Mosseri V; Jaulerry C; Brunin F; Point D; Validire P; Dubray B; Fridman WH; Rodriguez J
    Cancer; 1997 Apr; 79(7):1401-8. PubMed ID: 9083163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.